Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Artfinder is the art world's first certified B corporation that is on a mission to create a world where art benefits everyone. Operating in the $55 billion+ wall décor and online art market, the company is backed by Wellington Partners, and private investors in the UK, US and Switzerland. It has 60,000 customers, 6,000 artists and a collection of 470,000 artworks. The company believes in establishing direct contact with artists to select or commission work and negotiate prices. Customers have rated the company highly with 4.8+ Trustpilot reviews. The company will use the investment to supercharge its growth, grow its team and improve its platform.
days to go:
Expired
investment:
£834,056
WeVee is a platform that brings Electric Vehicles (EVs) into one place so that potential customers can browse across different models and makes, compare them, get relevant pricing, and configure a leasing plan, with the help of reliable EV experts. The company asserts that its pricing configurator pulls from some of the UK's top lenders such as Lex Autolease, LeasePlan, Arval UK, and ALD Automotive, using Application Programming Interface (API's) to show the best price for each lease configuration. WeVee argues that over 800 vehicles have been ordered on its portal to date. It has also earned £830,000 worth of revenue since launch and garnered 350+ 5-star Trustpilot reviews. WeVee will use the investment for technology development, marketing, contingency purposes, towards paying its tech, leadership, marketing, and operations teams, and upgrades to its IT hardware.
days to go:
Expired
investment:
£1,602,196
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.
days to go:
Expired
investment:
Withheld
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
eFOLDi a business that uses inventive engineering to unlock mobility in the less abled. It is a portable, lightweight and versatile mobility vehicle which can be folded to a suitcase size or used as a chair. The eFOLDi has an international patent, a registered trademark, passed various safety tests and won British invention of the year 2016
days to go:
Expired
investment:
£939,650
havebike is a bicycle repair business that collects, cleans, services and returns bicycles to owners at their doorstep, all via its app. The company asserts that it has been responsible for servicing approximately 2,500 specially designed bikes for the London Police and Ambulance Services since its launch in 2010. It also claims to be an authorised service agent for leading bicycle brands including, Brompton, Canyon and Ribble. havebike also holds a 'Shimano Service Centre' accreditation. It aspires to become a contender in the cycling market that was valued at £2.31 billion in late 2020. havebike's technology platform and booking system, Atlas, in late 2019 led to the company's Quarter To Date (QTD) revenues increasing by 484% and customer base by 22% as of February 2021. The company will use the investment for opening new workshops and mobile workshops (including fit-out) and cover marketing costs as it enters new markets to scale its business.
days to go:
Expired
investment:
£580,832
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
